Related Experiment Video
Updated: May 16, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
SLAMF7 Restrains Pro-Inflammatory Macrophage Activation to Counteract Doxorubicin-Induced Cardiotoxicity
Ao Liu1, Peiyuan Bai2, Hongmin You3
1Department of Cardiology, Zhongshan Hospital, Shanghai Institute of Cardiovascular Diseases and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; State Key Laboratory of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China; NHC Key Laboratory of Ischemic Heart Diseases, Shanghai, China; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai Institute of Medical Imaging, Shanghai, China.
SLAMF7 protects against doxorubicin-induced cardiotoxicity (DIC) by reducing inflammation. Restoring SLAMF7 levels effectively mitigated heart damage, highlighting its therapeutic potential in cancer treatment.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Doxorubicin-induced cardiotoxicity (DIC) is a major limitation in cancer therapy.
- Macrophage-mediated inflammation plays a key role in DIC pathogenesis.
Purpose of the Study:
- To investigate the role of SLAMF7 in doxorubicin-induced cardiotoxicity.
- To elucidate the underlying mechanisms of SLAMF7's protective effects.
Main Methods:
- Utilized SLAMF7 knockout mice to assess cardiotoxicity.
- Examined the interaction between SLAMF7 and TNF receptor-associated factor 6 (TRAF6).
- Measured nuclear factor κB (NF-κB) signaling, oxidative stress, and cytokine levels.
- Administered recombinant SLAMF7 protein to evaluate therapeutic efficacy.
Main Results:
- SLAMF7 deficiency exacerbated DIC and amplified inflammatory responses.
- SLAMF7 interacts with TRAF6 to attenuate NF-κB signaling.
- Reduced oxidative stress and proinflammatory cytokines were observed in the presence of SLAMF7.
- Recombinant SLAMF7 protein administration mitigated DIC.
Conclusions:
- SLAMF7 plays a critical protective role against DIC.
- SLAMF7 acts by modulating macrophage-mediated inflammation via the TRAF6/NF-κB pathway.
- SLAMF7 represents a promising therapeutic target for preventing and treating doxorubicin-induced cardiotoxicity.
